

Atlantic Research Group Client, Lev Pharmaceuticals, is Granted FDA Approval for Cinryze™

STAUNTON, VIRGINIA October 20, 2008 –

Atlantic Research Group (ARG) successfully managed the pivotal clinical trials for Lev Pharmaceuticals that resulted in FDA approval of Cinryze™.

“Our experienced and dedicated team ensured that Lev Pharmaceutical’s timelines were met and the trials were completed on budget. TrialVista®, our CTMS, was implemented throughout the study and was instrumental in the successful and timely completion of these studies,” said Paul Bishop, ARG’s Managing Partner.

On October 10, 2008 Lev Pharmaceuticals Inc. (LEVP.OB) announced that the U.S. Food and Drug Administration approved Cinryze™ for routine prophylaxis against angioedema attacks in adolescent and adult patients with hereditary angioedema, also known as C1 inhibitor deficiency. Cinryze™ is expected to be commercially available for prophylaxis against HAE later this year.

Lyle Camblos, ARG Managing Partner said, "This is an exciting time for HAE patients in the United States and we are excited to have been a part of the management of these clinical trials as well as the FDA approval of Cinryze™."

ARG also continues to assist Lev Pharmaceuticals' with the Cinryze™ roll-over studies being conducted.

About Atlantic Research Group, Inc. (ARG)

Atlantic Research Group is dedicated to efficiently and effectively supporting small and mid-size biopharma companies through the challenging clinical trial process. We’ve relied on our experience to create TrialVista®, the industry’s most innovative CTMS, which enables us to manage the dynamic requirement of bringing molecules to market.

For more information about Atlantic Research Group and *TrialVista*® please contact Atlantic Research Group directly at 540-213-0150, or visit Atlantic Research Group’s website at www.atlanticresearchgroup.com

###